Phoenix, AZ Clinical Trials Report — May 2026

For patients and healthy volunteers in Phoenix, AZ, May 2026 brings important updates on clinical trial opportunities. With a total of 848 clinical trials currently recruiting across 411 research facilities in the city, there are numerous ways to contribute to medical science. However, some opportunities require prompt action as enrollment windows are closing soon.

A total of 54 clinical trials in Phoenix are slated to conclude within the next 90 days. This includes 4 trials that are still accepting healthy volunteers, offering a chance to participate in research before their deadlines pass.

Urgent Opportunities: Trials Nearing Enrollment Close

Patients with specific health conditions should note the trials closing soon. These studies represent immediate opportunities to access new treatments or diagnostic approaches:

• End stage liver disease (2 trials)
• Depressive disorder, major (2 trials)
• Myasthenia gravis (2 trials)
• Obesity (2 trials)
• Amyotrophic lateral sclerosis (1 trial)
• Asthma (1 trial)
• Advanced NSCLC (1 trial)
• Benign prostatic hyperplasia (BPH) (1 trial)
• Alzheimer disease (1 trial)
• Bone graft; complications (1 trial)

New Research Horizons in Phoenix

This month, Phoenix saw the launch of 9 new clinical trials, a decrease compared to the 12 new trials in April and 13 in March 2026. Despite this slight dip, these new studies introduce important research across various health areas, primarily focusing on drug development with 7 new drug trials and 2 other types of studies.

Several notable Phase 2 and Phase 3 drug trials from major sponsors have opened, offering participants access to cutting-edge research:

• Novo Nordisk A/S is sponsoring two significant Phase 3 trials:
  • NCT07567001: "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This large study aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with heart failure and excess body weight.
  • NCT07564414: "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks 2,500 participants to assess the safety and effectiveness of CagriSema for weight loss in people with obesity, with or without Type 2 Diabetes.
• AstraZeneca is leading NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)." This Phase 3 study involves 670 participants and aims to demonstrate the superiority of AZD2265 in treating metastatic castration-resistant prostate cancer.
• Eli Lilly and Company is sponsoring NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This Phase 3 trial involves 550 participants and investigates the clinical benefit of annual doses of donanemab for participants who previously took the drug.
• Immuneering Corporation is behind NCT07562152, "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma." This Phase 3 study with 510 participants evaluates the safety and efficacy of atebimetinib in combination with modified GnP compared to standard of care.
• Apollo Therapeutics Ltd is conducting NCT07599813, "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis." This Phase 2b study involves 280 participants and is a randomized, double-blind, placebo-controlled study.

New trials this month are focused on conditions such as congenital heart disease (2 trials) and obesity (2 trials). Several new trials also address dermatological conditions, including atopic dermatitis, dermatitis, dermatologic disease, eczema, and eczema atopic dermatitis, each with 1 new trial.

Phoenix's Leading Research Institutions

Phoenix is a hub for medical research, with several facilities consistently running a high volume of clinical trials. These institutions are key destinations for those looking to participate:

• Phoenix Children's Hospital (including Phoenix Childrens Hospital) leads with a combined total of 96 trials.
• The Mayo Clinic system (including Mayo Clinic Hospital in Arizona, Mayo Clinic Arizona, Mayo Clinic, and Mayo Clinic Hospital) collectively offers 138 trials.
• Cancer Center at Saint Joseph's (including St. Joseph's Hospital and Medical Center) has a combined total of 66 trials.
• Barrow Neurological Institute is conducting 26 trials.
• Arizona State University is running 12 trials.
• Associated Retina Consultants is involved in 11 trials.

These facilities provide a wide range of research opportunities, from pediatric care at Phoenix Children's Hospital to oncology at the Cancer Center at Saint Joseph's and diverse medical fields at the Mayo Clinic system and Arizona State University.

Participation Details and Healthy Volunteer Opportunities

For individuals without specific medical conditions, there are currently 58 clinical trials recruiting healthy volunteers in Phoenix. While none of the 9 new trials opened this month are seeking healthy participants, the 4 closing-soon trials that do accept healthy volunteers highlight the need for timely enrollment.

Regarding participant demographics for the new trials, all 9 include older adults, ensuring that senior populations have ample opportunities to contribute to medical science. There is 1 new trial specifically for male participants, but none are exclusively for children or females this month.

Industry sponsors are driving the majority of new research in Phoenix, with 7 new trials sponsored by companies like Carelon Research (2 trials), Novo Nordisk A/S (2 trials), Apollo Therapeutics Ltd (1 trial), Immuneering Corporation (1 trial), Myosin Therapeutics Inc. (1 trial), Eli Lilly and Company (1 trial), and AstraZeneca (1 trial). The remaining 2 new trials are sponsored by other entities.

Exploring Options Beyond Phoenix

While Phoenix offers extensive clinical trial opportunities, individuals in Arizona may also find suitable studies in nearby cities. Other communities with active trials include:

• Scottsdale (5 trials)
• Gilbert (4 trials)
• Chandler (3 trials)
• Tempe (3 trials)
• Tucson (3 trials)
• Flagstaff (1 trial)
• Glendale (1 trial)
• Goodyear (1 trial)

As May progresses, Phoenix's research community continues to advance medical knowledge, offering diverse avenues for individuals to contribute to the future of healthcare and explore new treatment options.